Please enable JavaScript to continue using this application.

Compare $CHRS vs $NKTX | Chartloom

Compare

$CHRS vs $NKTX

Coherus Oncology Inc · Nkarta Inc

CHRS

Coherus Oncology Inc

NKTX

Nkarta Inc

Compare $CHRS vs $NKTX

Comparing Coherus Oncology Inc and Nkarta Inc

CHRSCoherus Oncology Inc

NKTXNkarta Inc

CHRSCoherus Oncology Inc

Market cap

$165M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.04x

Rev growth (TTM)

-64.3%

YTD performance

-21.9%

52W performance

-39.2%

FCF yield

-112.7%

NKTXNkarta Inc

Market cap

$161M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

20.3%

52W performance

7.7%

FCF yield

-58.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CHRS

NKTX

Detailed metrics comparison

CHRS

Coherus Oncology Inc

NKTX

Nkarta Inc

Market Cap

CHRS$165M

NKTX$161M

Enterprise Value

CHRS$134M

NKTX$136M

Price

CHRS$1.07

NKTX$2.25

P/E Ratio

CHRSN/A

NKTXN/A

P/S Ratio

CHRS3.24x

NKTX0.00x

EV/Sales

CHRS2.63x

NKTX0.00x

EV/EBITDA

CHRS2.57x

NKTX0.00x

P/B Ratio

CHRS2.95x

NKTX0.74x

P/FCF Ratio

CHRSN/A

NKTXN/A

EV/FCF

CHRS-0.72x

NKTX-1.45x

PEG Ratio

CHRSN/A

NKTXN/A

Forward P/E (NTM)

CHRSN/A

NKTXN/A

Forward P/S (NTM)

CHRS2.04x

NKTXN/A

Revenue (TTM)

CHRS$51M

NKTX$0

Revenue Growth (YoY)

CHRS-64.3%

NKTXN/A

Forward Rev Growth

CHRS67.8%

NKTX2561.2%

Gross Margin (TTM)

CHRS68.9%

NKTX0.0%

Operating Margin (TTM)

CHRS0.0%

NKTX0.0%

EBITDA Margin (TTM)

CHRS-288.0%

NKTX0.0%

Net Margin (TTM)

CHRS-259.4%

NKTX0.0%

FCF Margin (TTM)

CHRS-365.2%

NKTXN/A

Net Income (TTM)

CHRS$-132M

NKTX$-117M

FCF (TTM)

CHRS$-186M

NKTX$-94M

EPS (TTM)

CHRS-$0.85

NKTX-$1.57

ROE (TTM)

CHRS-18336.0%

NKTX-3964.0%

ROA (TTM)

CHRS-4290.0%

NKTX-3045.0%

ROIC (TTM)

CHRS-10716.0%

NKTX-3964.0%

Cash

CHRS$83M

NKTX$25M

Debt

CHRS$52M

NKTX$0

Net Cash/Debt

CHRS$31M

NKTX$25M

Current Ratio (TTM)

CHRS1.77x

NKTX7.98x

Quick Ratio (TTM)

CHRS1.58x

NKTX7.76x

Debt/Equity (TTM)

CHRS0.85x

NKTX0.00x

Debt/Assets (TTM)

CHRS0.0%

NKTX0.0%

Interest Coverage (TTM)

CHRSN/A

NKTXN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

NKTX0.00x

Beta

CHRS0.99

NKTX1.19

52W Performance

CHRS-39.2%

NKTX7.7%

YTD Performance

CHRS-21.9%

NKTX20.3%

% from 52W High

CHRS-59.1%

NKTX-39.5%

% from 52W Low

CHRS9.9%

NKTX32.4%

Asset Turnover (TTM)

CHRS0.17x

NKTX0.00x

FCF Yield (TTM)

CHRS-112.7%

NKTX-58.3%

Earnings Yield (TTM)

CHRS-80.1%

NKTX-72.9%

Dividend Yield (TTM)

CHRSN/A

NKTXN/A

Rule of 40

CHRS-429.5

NKTX0.0

EV/GP/RG

CHRS0.05

NKTXN/A

Ticker research

View CHRS research View NKTX research

Metric	CHRS Coherus Oncology Inc	NKTX Nkarta Inc
Market & Valuation
Market Cap	$165M	$161M
Enterprise Value	$134M	$136M
Price	$1.07	$2.25
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	0.00x
EV/Sales	2.63x	0.00x
EV/EBITDA	2.57x	0.00x
P/B Ratio	2.95x	0.74x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	-1.45x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	N/A
Revenue & Growth
Revenue (TTM)	$51M	$0
Revenue Growth (YoY)	-64.3%	N/A
Forward Rev Growth	67.8%	2561.2%
Profitability
Gross Margin (TTM)	68.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	0.0%
Net Margin (TTM)	-259.4%	0.0%
FCF Margin (TTM)	-365.2%	N/A
Net Income (TTM)	$-132M	$-117M
FCF (TTM)	$-186M	$-94M
EPS (TTM)	-$0.85	-$1.57
ROE (TTM)	-18336.0%	-3964.0%
ROA (TTM)	-4290.0%	-3045.0%
ROIC (TTM)	-10716.0%	-3964.0%
Financial Health
Cash	$83M	$25M
Debt	$52M	$0
Net Cash/Debt	$31M	$25M
Current Ratio (TTM)	1.77x	7.98x
Quick Ratio (TTM)	1.58x	7.76x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.19
52W Performance	-39.2%	7.7%
YTD Performance	-21.9%	20.3%
% from 52W High	-59.1%	-39.5%
% from 52W Low	9.9%	32.4%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.00x
FCF Yield (TTM)	-112.7%	-58.3%
Earnings Yield (TTM)	-80.1%	-72.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	0.0
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View NKTX research

Valuation

P/S Ratio

NKTX

0.00x

CHRS

3.24x

EV/FCF

NKTX

-1.45x

CHRS

-0.72x

Growth & revenue

Revenue Growth TTM

CHRS

-64.3%

Forward Revenue Growth

NKTX

2561.2%

CHRS

67.8%

Profitability & performance

Gross Margin

CHRS

68.9%

NKTX

0.0%

ROE

NKTX

-3964.0%

CHRS

-18336.0%

FCF Yield %

NKTX

-58.3%

CHRS

-112.7%

52-Week Performance

NKTX

7.7%

CHRS

-39.2%

Detailed metrics comparison

CHRS

Coherus Oncology Inc

NKTX

Nkarta Inc

Market Cap

CHRS$165M

NKTX$161M

Enterprise Value

CHRS$134M

NKTX$136M

Price

CHRS$1.07

NKTX$2.25

P/E Ratio

CHRSN/A

NKTXN/A

P/S Ratio

CHRS3.24x

NKTX0.00x

EV/Sales

CHRS2.63x

NKTX0.00x

EV/EBITDA

CHRS2.57x

NKTX0.00x

P/B Ratio

CHRS2.95x

NKTX0.74x

P/FCF Ratio

CHRSN/A

NKTXN/A

EV/FCF

CHRS-0.72x

NKTX-1.45x

PEG Ratio

CHRSN/A

NKTXN/A

Forward P/E (NTM)

CHRSN/A

NKTXN/A

Forward P/S (NTM)

CHRS2.04x

NKTXN/A

Revenue (TTM)

CHRS$51M

NKTX$0

Revenue Growth (YoY)

CHRS-64.3%

NKTXN/A

Forward Rev Growth

CHRS67.8%

NKTX2561.2%

Gross Margin (TTM)

CHRS68.9%

NKTX0.0%

Operating Margin (TTM)

CHRS0.0%

NKTX0.0%

EBITDA Margin (TTM)

CHRS-288.0%

NKTX0.0%

Net Margin (TTM)

CHRS-259.4%

NKTX0.0%

FCF Margin (TTM)

CHRS-365.2%

NKTXN/A

Net Income (TTM)

CHRS$-132M

NKTX$-117M

FCF (TTM)

CHRS$-186M

NKTX$-94M

EPS (TTM)

CHRS-$0.85

NKTX-$1.57

ROE (TTM)

CHRS-18336.0%

NKTX-3964.0%

ROA (TTM)

CHRS-4290.0%

NKTX-3045.0%

ROIC (TTM)

CHRS-10716.0%

NKTX-3964.0%

Cash

CHRS$83M

NKTX$25M

Debt

CHRS$52M

NKTX$0

Net Cash/Debt

CHRS$31M

NKTX$25M

Current Ratio (TTM)

CHRS1.77x

NKTX7.98x

Quick Ratio (TTM)

CHRS1.58x

NKTX7.76x

Debt/Equity (TTM)

CHRS0.85x

NKTX0.00x

Debt/Assets (TTM)

CHRS0.0%

NKTX0.0%

Interest Coverage (TTM)

CHRSN/A

NKTXN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

NKTX0.00x

Beta

CHRS0.99

NKTX1.19

52W Performance

CHRS-39.2%

NKTX7.7%

YTD Performance

CHRS-21.9%

NKTX20.3%

% from 52W High

CHRS-59.1%

NKTX-39.5%

% from 52W Low

CHRS9.9%

NKTX32.4%

Asset Turnover (TTM)

CHRS0.17x

NKTX0.00x

FCF Yield (TTM)

CHRS-112.7%

NKTX-58.3%

Earnings Yield (TTM)

CHRS-80.1%

NKTX-72.9%

Dividend Yield (TTM)

CHRSN/A

NKTXN/A

Rule of 40

CHRS-429.5

NKTX0.0

EV/GP/RG

CHRS0.05

NKTXN/A

Ticker research

View CHRS research View NKTX research

Metric	CHRS Coherus Oncology Inc	NKTX Nkarta Inc
Market & Valuation
Market Cap	$165M	$161M
Enterprise Value	$134M	$136M
Price	$1.07	$2.25
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	0.00x
EV/Sales	2.63x	0.00x
EV/EBITDA	2.57x	0.00x
P/B Ratio	2.95x	0.74x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	-1.45x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	N/A
Revenue & Growth
Revenue (TTM)	$51M	$0
Revenue Growth (YoY)	-64.3%	N/A
Forward Rev Growth	67.8%	2561.2%
Profitability
Gross Margin (TTM)	68.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	0.0%
Net Margin (TTM)	-259.4%	0.0%
FCF Margin (TTM)	-365.2%	N/A
Net Income (TTM)	$-132M	$-117M
FCF (TTM)	$-186M	$-94M
EPS (TTM)	-$0.85	-$1.57
ROE (TTM)	-18336.0%	-3964.0%
ROA (TTM)	-4290.0%	-3045.0%
ROIC (TTM)	-10716.0%	-3964.0%
Financial Health
Cash	$83M	$25M
Debt	$52M	$0
Net Cash/Debt	$31M	$25M
Current Ratio (TTM)	1.77x	7.98x
Quick Ratio (TTM)	1.58x	7.76x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.19
52W Performance	-39.2%	7.7%
YTD Performance	-21.9%	20.3%
% from 52W High	-59.1%	-39.5%
% from 52W Low	9.9%	32.4%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.00x
FCF Yield (TTM)	-112.7%	-58.3%
Earnings Yield (TTM)	-80.1%	-72.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	0.0
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View NKTX research